ASCO 2026 | INO-3107 and B-cell immunity: implications for HPV-associated cancers
Nabil Saba
• 1 Jun 2026
Nabil Saba, MD, Emory University, Atlanta, GA, discusses the importance of understanding B-cell responses in patients with recurrent respiratory papillomatosis patients treated with INO-3107, highlighting the potential to inform the development of DNA-based or B-cell–engaging immunotherapies in other HPV-associated diseases, such as head and neck squamous cell carcinoma and oropharynx cancer. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
